|
Orthologous residues
|
|
Rb (human): S811‑p, Rb (mouse): S804‑p, Rb (rat): S803‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
'stem, neural'
|
|
Cellular systems studied:
primary cultured cells
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
AMPKA1 (mouse)
|
pharmacological inhibitor of upstream enzyme, genetic knockout/knockin of upstream enzyme, modification site within consensus motif
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF, aFGF
|
|
|
|
increase
|
|
|
compound C
|
aFGF, EGF
|
|
|
inhibit treatment-induced increase
|
|
|
glucose
|
|
|
|
increase
|
|
|
compound C
|
glucose
|
|
|
inhibit treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
cell cycle regulation, cell growth, altered
|
